006 Using Serum 17-hydroxyprogesterone to Evaluate Changes in Intratesticular Testosterone Among Men Receiving Therapies That Alter Serum Testosterone

Intratesticular testosterone (ITT) is of paramount importance for the initiation and maintenance of spermatogenesis. Unfortunately, there currently exists no serum biomarker which accurately reflects ITT levels. Serum 17-hydroxyprogesterone (17-OHP) has been shown to be a promising serum biomarker with experimental studies demonstrating good correlation between serum 17-OHP and ITT. As such, we sought to analyze 17-OHP response to various therapies that alter serum testosterone. We performed a prospective study from July 2018 to June 2019. All men undergoing various agents that change serum testosterone (testosterone replacement therapies (TRT), clomiphene citrate, human chorionic gonadotropin and anastrazole were evaluated prior to therapy and at 3 months after therapy. We utilized serum 17-OHP measurements men who presented to our clinic for complaints other than hypogonadism to serve as a control group. We excluded men who were previously on TRT. According to the data distribution, we reported the median and interquartile ranges [25-75] and utilize the U Mann Whitney or Wilcoxon test as required.